PMID- 36036412
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220830
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 122
IP  - 8
DP  - 2022
TI  - [Neurotrophic therapy in the treatment of a comorbid patient with cerebrovascular 
      pathology and diabetes mellitus].
PG  - 112-119
LID - 10.17116/jnevro2022122081112 [doi]
AB  - OBJECTIVE: To study the use of Cellex in a population of patients aged 45 to 75 
      years with ischemic stroke and TIA, with a history of type 2 diabetes mellitus 
      (T2DM), with diabetic distal symmetric polyneuropathy. MATERIAL AND METHODS: The 
      study involved 80 patients (men - 52.5%, women - 47.5%) in the rehabilitation 
      period of stroke, including TIA, developed in T2DM. The patients were divided 
      into 2 groups (40 people in each): in the 1st group, patients received Cellex 1.0 
      ml subcutaneously 1 time per day in addition to routine practice; the 2nd group 
      received only routine practice. Cellex was prescribed in the form of two 10-day 
      treatment courses with a break of 1 month. The range of patients examination 
      during the whole study period (4 visits, 65 days) included an assessment of 
      neurological symptoms (NIHSS, NISLL, DN-4, TSS scales), neurophysiological 
      examination (EMNG), analysis of daily activity (SF-36 questionnaire, the 
      Rivermead Mobility Index, the Modified Rankin Scale), the emotional state 
      assessment on the scale and the effects of therapy on the Clinical Global 
      Impression Scale. RESULTS AND CONCLUSION: The clinical efficacy of the drug was 
      shown in the form of an improvement of clinical parameters and data on EMNG of 
      the lower extremities on the 60th day of the study. Improvement was observed in 
      17.5% of patients in the 1st group, while in the 2nd group deterioration was 
      observed in 15.0% of patients, as evidenced by the presence of statistically 
      significant differences. The study drug was also shown to be well tolerated and 
      safe. CONCLUSION: The use of the Cellex is effective and safe in patients with 
      T2DM in the recovery period of stroke.
FAU - Kurushina, O V
AU  - Kurushina OV
AUID- ORCID: 0000-0003-4364-0123
AD  - Volgograd State Medical University, Volgograd, Russia.
FAU - Barulin, A E
AU  - Barulin AE
AUID- ORCID: 0000-0001-7264-3580
AD  - Volgograd State Medical University, Volgograd, Russia.
FAU - Chernovolenko, E P
AU  - Chernovolenko EP
AUID- ORCID: 0000-0001-6517-9062
AD  - Volgograd State Medical University, Volgograd, Russia.
LA  - rus
PT  - Journal Article
TT  - Neirotroficheskaya terapiya komorbidnykh bol'nykh s tserebrovaskulyarnoi 
      patologiei i sakharnym diabetom.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
SB  - IM
MH  - Comorbidity
MH  - *Diabetes Mellitus, Type 2
MH  - *Diabetic Neuropathies
MH  - Female
MH  - Humans
MH  - *Ischemic Attack, Transient
MH  - Male
MH  - *Stroke
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cellex
OT  - cerebrovascular diseases
OT  - diabetes mellitus (DM)
OT  - diabetic distal symmetric polyneuropathy (DSPN)
OT  - neuroprotectors
OT  - stroke
EDAT- 2022/08/30 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/08/29 06:58
PHST- 2022/08/29 06:58 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
AID - 10.17116/jnevro2022122081112 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(8):112-119. doi: 
      10.17116/jnevro2022122081112.